Rituximab-based treatments in Waldenström's macroglobulinemia.

The anti-CD20 monoclonal antibody rituximab has shown activity in approximately one third of patients with Waldenström's Macroglobulinemia (WM). Because this agents is nonmyelosuppressive, several studies have assessed its combination with chemotherapeutic agents such as fludarabine, cladribine, cyclophosphamide, and doxorubicin. These regimens induce at least partial response in > 70% of previously untreated patients. Recent data suggest that prolonged exposure to nucleoside-containing regimens should be avoided because of concerns of myelodysplasia and disease transformation. Rituximab has also been combined with thalidomide, which is an active and nonmyelosuppressive regimen. The rituximab-based combination represents today the most commonly used primary treatment for WM.

[1]  V. Preedy,et al.  International Prognostic Scoring System , 2010 .

[2]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[3]  M. Dimopoulos,et al.  The International Prognostic Scoring System for Waldenström’s macroglobulinemia is applicable in patients treated with rituximab-based regimens , 2008, Haematologica.

[4]  M. Pasmantier,et al.  Thalidomide and rituximab in Waldenstrom macroglobulinemia. , 2004, Blood.

[5]  J. Tamburini,et al.  Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM) , 2007 .

[6]  F. Ferrara,et al.  Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results , 2007 .

[7]  G. Martinelli,et al.  Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab. , 2007 .

[8]  R. Fonseca,et al.  Phase II Pilot Study of Rituximab + CHOP in Patients with Newly Diagnosed Waldenström’s Macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02). , 2007 .

[9]  M. Dimopoulos,et al.  Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Treon,et al.  Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues , 2007 .

[11]  B. Barlogie,et al.  International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM). , 2006 .

[12]  V. Leblond,et al.  Fludarabine Plus Cyclophosphamide and Rituximab (RFC) in Waldenström’s Macroglobulinemia (WM): Results in 21 Patients (pts). , 2006 .

[13]  M. Dimopoulos,et al.  Rituximab therapy in monoclonal IgM-related neuropathies , 2006, Leukemia & lymphoma.

[14]  E. Kimby,et al.  Extended rituximab therapy in Waldenström's macroglobulinemia. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Rue,et al.  Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia , 2004, Cancer.

[16]  E. Kimby,et al.  Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia. , 2004 .

[17]  M. Rue,et al.  Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) , 2004, Leukemia & lymphoma.

[18]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Dimopoulos,et al.  Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. , 2002, Clinical lymphoma.

[20]  M. Dimopoulos,et al.  Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.